期刊文献+

普萘洛尔及异丙肾上腺素对体外培养婴儿血管瘤内皮细胞增殖和血管内皮生长因子、碱性成纤维细胞生长因子表达的影响 被引量:7

In vitro effects of propranolol and isoproterenol on proliferation of cultured infantile hemangioma endothelial cells and expressions of vascular endothelial growth factors and basic fibroblast growth factor
原文传递
导出
摘要 目的:探讨普萘洛尔及异丙肾上腺素在体外对婴儿血管瘤内皮细胞增殖及血管内皮细胞生长因子(VEGF、VEGF-2)、人碱性成纤维细胞生长因子(bFGF)表达的影响。方法将体外培养的2~3代增殖期婴儿血管瘤内皮细胞分为普萘洛尔组和异丙肾上腺素组,其中普萘洛尔组分别换浓度为10、15、20 mg/L 普萘洛尔工作液(10、15、20 mg/L 普萘洛尔组)、空白 EGM-2培养基(空白组)和含0.16% DMSO EGM-2培养基(DMSO组)培养,而异丙肾上腺素组分别换5、10、20 mg/L 异丙肾上腺素工作液(5、10、20 mg/L 异丙肾上腺素组)和空白EGM-2培养基(空白组)培养。采用 MTT 法测定24、48、72、96 h 时各组血管瘤内皮细胞的增殖情况,ELISA 法测定培养24、48 h 时各组细胞培养上清液中 VEGF、VEGF-2、bFGF 的浓度。结果培养24、48 h 时,10、15、20 mg/L 普萘洛尔组血管瘤内皮细胞增殖差异无统计学意义(H 值分别为1.152、2.643,均 P 〉0.05);72、96 h 时,20 mg/L 普萘洛尔组血管瘤内皮细胞的增殖明显低于空白组(P 〈0.05),而空白组、DMSO 组及10、15 mg/L 普萘洛尔组间差异均无统计学意义。各浓度普萘洛尔、异丙肾上腺素作用24 h 时均对 VEGF、VEGF-2、bFGF 水平有一定影响。48 h 时,15、20 mg/L 普萘洛尔组 VEGF 水平均较空白组显著下降,同时10、15、20 mg/L 普萘洛尔组VEGF-2、bFGF 水平也均较空白组显著下降(P 〈0.05);而5、10、20 mg/L 异丙肾上腺素组 VEGF 水平均较空白组显著升高(P 〈0.05),20 mg/L 异丙肾上腺素组 VEGF-2、bFGF 水平均显著高于空白组及5、10 mg/L 异丙肾上腺素组(P 〈0.05)。结论一定浓度普萘洛尔作用于增殖期婴儿血管瘤内皮细胞一定时间后能够抑制细胞生长,而异丙肾上腺素反之,两者对细胞因子表达的影响作用也相反,因此推断普萘洛尔治疗婴儿血管瘤的机制可能与β肾上腺素能受体及其下游信号转导影响相关细胞因子表达相关。 Objective To evaluate in vitro effects of propranolol and isoproterenol on proliferation of infantile hemangioma endothelial cells(IHECs)as well as expressions of vascular endothelial growth factors(VEGF and VEGF-2) and human basic fibroblast growth factor (bFGF). Methods The second - third passage endothelial cells derived from the proliferative phase of infantile hemangioma were divided into propranolol and isoproterenol groups. The propranolol group was further classified into 5 groups to be treated with propranolol solutions at concentrations of 10, 15, 20 mg/L, EGM-2 medium (blank control group 1), or EGM-2 medium containing 0.16% DMSO (DMSO group), while the isoproterenol group was classified into 4 groups to be treated with isoproterenol solutions at concentrations of 5, 10, 20 mg/L or EGM-2 medium(blank control group 2). Methyl thiazolyl tetrazolium(MTT)assay was performed to evaluate cellular proliferative activity in these propranolol groups at 24, 48, 72 and 96 hours separately, enzyme-linked immunosorbent assay (ELISA)to measure VEGF, VEGF-2 and bFGF lev els in culture supernatants of IHECs at 24 and 48 hours separately. Results The proliferative activity of IHECs showed no significant differences between 10-, 15- and 20-mg/L propranolol groups at either 24 or 48 hours (H = 1.152, 2.643, respectively, both P 〉 0.05), or between the blank control group 1, DMSO group, and 10- and 15-mg/L propranolol groups at either 72 or 96 hours, but significantly decreased in the 20-mg/L propranolol group compared with the blank control group 1 at 72 and 96 hours (both P 〈 0.05). The 24-hour treatments with propranolol or isoproterenol at the above concentrations all affected the expressions of VEGF, VEGF-2 and bFGF to different degrees. At 48 hours, there was a significant decrease in VEGF levels in 15- and 20-mg/L propranolol groups, as well as in VEGF-2 and bFGF levels in 10-, 15- and 20-mg/L propranolol groups compared with the blank control group 1 (all P 〈 0.05), but a significant increase in VEGF levels in 5-, 10- and 20-mg/L isoproterenol groups compared with the blank control group 2 (all P 〈 0.05), as well as in VEGF-2 and bFGF levels in the 20-mg/L isoproterenol group compared with the blank control group 2, 5- and 10-mg/L isoproterenol groups (all P 〈 0.05). Conclusions The treatment with propranolol at certain concentrations for certain durations can suppress the growth of, as well as expressions of VEGF, VEGF-2 and bFGF in, endothelial cells derived from the proliferative phase of infantile hemangioma, whereas that with isoproterenol has opposite effects. The therapeutic mechanism of propranolol in infantile hemangioma may be associated with expressions of β-adrenergic receptors and their downstream signal transduction-related cytokines.
出处 《中华皮肤科杂志》 CAS CSCD 北大核心 2016年第3期158-162,共5页 Chinese Journal of Dermatology
关键词 血管瘤 内皮细胞 普萘洛尔 异丙肾上腺素 成纤维细胞生长因子2 内皮生长因子 Hemangioma Endothelial cells Propranolol Isoproterenol Fibroblast growth factor 2 Endothelial growth factors
  • 相关文献

参考文献19

  • 1North PE, Waner M, Brodsky MC. Are infantile hemangiomas of placental origin[J]. Ophthalmology, 2002, 109(4): 633-634. DOI: 10.1016/S0161-6420(02)01071-0.
  • 2R6gnier S, Dupin N, Le Danff C, et al. Endothelial ceils in infantile haemangiomas originate from the child and not from the mother (a fluorescence in situ hybridization-based study)[J 1. Br J Dermatol, 2007, 157( 1 ): 158-160. DOI: 10.1111/j. 1365-2133.2007.07922.x.
  • 3Zhang GY, Yi CG, Li X, et al. Proliferation hemangiomas formation through dual mechanism of vascular endothelial growth factor mediated endothelial progenitor ceils proliferation and mobilization through matrix metalloproteinases 9[J]. Med Hypotheses, 2008, 70 (4): 815-818. DOI: 10.1016/j.mehy.2007.06.042.
  • 4Takahashi K, Mulliken JB, Kozakewich HP, et al. Cellular markers that distinguish the phases of childhood [Jl. J Clin Invest, 10.1172/JCI117241. hemangioma during infancy and 1994, 93 (6): 2357-2364. DOI:.
  • 5Gordillo GM, Onat D, Stockinger M, et al. A key angiogenic role of monocyte chemoattractant protein-1 inhemangioendothelioma proliferation [ J ]. Am J Physiol Cell Physiol, 2004, 287 (4): C866- C873. DOI: 10.1152/ajpcell.00238.2003.
  • 6Eum SY, Maghni K, Hamid Q, et al. Inhibition of allergic airways inflammation and airway hyperresponsiveness in mice by dexamethasone: role of eosinophils, IL-5, eotaxin, and IL-13 [J]. J Allergy Clin Immunol, 2003, 111 ( 5 ): 1049-1061.
  • 7Bauland CG, Smit JM, Bartelink LR, et al. Hemangioma in the newborn: increased incidence after chorionie villus sampling [J~. Prenat Diagu, 2010, 30( 10): 913-917. DOI: 10.1002/pd.2562.
  • 8L~aut6-Labr~ze C, Dumas de la Roque E, Hubiche T, et al. Propranolol for severe hemangiomas of infancy [J]. N Engl J Med, 2008, 358(24): 2649-2651. DOI: 10.1056/NEJMc0708819.
  • 9Buckmiller LM, Munson PD, Dyamenahalli U, et al. Pwpranolol for infantile hemangiomas: early experience at a tertiary vascular anomalies center[J]. Laryngoscope, 2010, 120(4): 676-681. DOI: 10. lO02/lary.20807.
  • 10Sans V, de la Roque ED, Berge J, et al. Propranolol for severe infantile hemangiomas: follow-up report [J]. Pediatrics, 2009, 124 (3): eg23-e431. DOI: 10.1542/peds.2008-3458.

二级参考文献53

  • 1刘江斌,肖现民,盛民立.雌激素和血管内皮细胞生长因子促进血管瘤增殖的体外实验研究[J].中华小儿外科杂志,2004,25(3):231-234. 被引量:24
  • 2Haggstrom AN Drolet BA.婴幼儿血管瘤的前瞻性研究:人口统计学及围产期特点[J].中国口腔颌面外科杂志,2007,5(3):179-179. 被引量:16
  • 3Mulliken JB, Young AE. Vascular birthmarks: hemangiomas and malformations[M]. Philadelphia: W. B. Saunders Co. ,1988: 63 - 76.
  • 4Folkman J. Clinical applications of research on angiogenesis [J]. N Engl J Med, 1995, 333(26) : 1757 -1763.
  • 5Yanase T, Tamura M, Fujita K, et al. Inhibitory effect of angiogenesis inhibitor on tumor growth and metastasis of human cell lines in vitro and in vivo [ J]. Cancer Res, 1993, 53 ( 1 ) : 5233 - 5236.
  • 6Smolinski KN, Yan AC. Hemangiomas of infancy: clinical and biological characteristics [ J ]. Clin Pedatr, 2005, 44(9) : 747 - 766.
  • 7Esterly N. Cutaneous hemangiomas, vascular stains and malformations, and associated syndromes [ J]. Curr Probl Dermatol, 1995, 7(3) : 65 -108.
  • 8Sarkar M, Mulliken J, Kozakewich H, et al. Thrombocytopenic coagulopathy (Kasabach-Merritt phenomenon ) is associated with kaposiform Hemangioendothelioma and not common infantile hemangioma [J]. Plast Reconstr Sttrg, 1997, 100(6) : 1377 -1386.
  • 9Liekens S, Verbeken E, Vandeputte M, et al. A novel animal model for hemangiomas : inhibition of hemangioma development by the angiogenesis inhibitor TNP - 470 [ J ]. Cancer Res, 1999, 59 (10) : 2376 -2383.
  • 10Ferrara N, Hillan K J, Gerber HP, et al. Discovery and development of bevacizumab, an anti-VEGF antibody for treating cancer [J]. Nat Rev Drug Discov, 2004, 3(5) : 391 -400.

共引文献13

同被引文献58

引证文献7

二级引证文献18

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部